Minneapolis' DiaMedica Therapeutics Inc. raised additional gross proceeds of $2.5 million through a private placement of 10,534,059 units priced 24.5 cents each.
The biopharmaceutical company had previously raised $3.8 million and plans to use the $6.3 million to complete a mid-stage study of its drug DM199 to treat acute ischemic stroke.